Overview

Dose Milnacipran Prevent Depressive Symptoms in Patients With Acute Stroke?

Status:
Unknown status

Trial end date:
2011-09-01

Target enrollment:
0

Participant gender:
All

Summary

Depression is one of the important psychiatric sequelae after stroke. The prevalence of post stroke depression (PSD) is approximately 20-40%. Depression comorbid with stroke has been found to be associated with increased disability, cognitive function decline, poorer rehabilitation outcome and higher mortality rate.We are going to conduct a trial of prevention of psot stroke depression by prescribing milnacipran in advance.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Chang Gung Memorial Hospital

Treatments:

Levomilnacipran
Milnacipran

Criteria

Inclusion Criteria:

- Consecutive admission due to first or recurrent ischemic stroke (image proved) and
stroke occurred in preceding 4 weeks before admission. The onset of stroke was defined
as the occurrence of abnormal neurological symptoms according to the patients'
statement. The following period is 12 months after being included (for the first and
third study aims), and follow for another 24 months to study the immunological aspect
of PSD (for the second study aim).

Exclusion Criteria:

- TIA (transit ischemic attack)

- Impairment of communication or cognitive function (MMSE<15)

- Past history of depression, psychosis, severe substance abuse

- Taking antidepressants at least 2 weeks prior to stroke

- Concurrent possible depression (Ham-D>10)